Diagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid
Diagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid
复制标题
DOI：
10.1128/jcm.02913-15
复制
发表时间：
2016-02-01
影响因子：
9.4
通讯作者：
Rijnders, B. J. A.
中科院分区：
文献类型：
--
作者：
Chong, G. M.;Maertens, J. A.;Rijnders, B. J. A.
检测脑脊液（CSF）中半乳甘露聚糖（GM）抗原的存在可能有助于诊断脑曲霉病（CA）。然而，使用CSF GM试验作为诊断试验的研究很少。我们通过比较疑似和确诊CA患者与非CA患者在不同截止点的CSF GM光密度指数（ODI）来评估其诊断性能。选择2004年至2014年在2家三级转诊医院诊断疑似CA且CSF GM ODI已确定的患者。使用了欧洲癌症/侵袭性传染病研究组织真菌病组（EORTC/MSG）对侵袭性曲霉病和CA的定义，但排除了待验证的测试（即CSF GM测试）作为微生物EORTC/MSG标准。研究人群包括44例患者（4例确诊CA， 13例可能CA， 27例无CA）。17例CA患者中，15例CSF GM ODI为>= 2.0。在27例无CA的患者中，26例CSF GM ODI为
Testing cerebrospinal fluid (CSF) for the presence of galactomannan (GM) antigen may help in diagnosing cerebral aspergillosis (CA). However, the use of the CSF GM test as a diagnostic test has been little studied. We evaluated its diagnostic performance by comparing the CSF GM optical density indexes (ODI) at different cutoffs in patients with probable and proven CA to those in patients without CA. Patients from 2 tertiary referral hospitals with suspected CA between 2004 and 2014 and in whom CSF GM ODI had been determined were selected. European Organization for Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) definitions of invasive aspergillosis and CA were used, but with the exclusion of the test to be validated (i.e., the CSF GM test) as a microbiological EORTC/MSG criterion. The study population consisted of 44 patients (4 with proven CA, 13 with probable CA, and 27 with no CA). Of the 17 patients with CA, 15 had a CSF GM ODI of >= 2.0. Of 27 patients without CA, 26 had a CSF GM ODI of